349 related articles for article (PubMed ID: 28645563)
41. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
42. Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
Shen YN; He HG; Shi Y; Cao J; Yuan JY; Wang ZC; Shi CF; Zhu N; Wei YP; Liu F; Huang JL; Yang GS; Lu JH
Mol Carcinog; 2017 Feb; 56(2):751-760. PubMed ID: 27478926
[TBL] [Abstract][Full Text] [Related]
43. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Jiang X; Feng K; Zhang Y; Li Z; Zhou F; Dou H; Wang T
Oncotarget; 2015 May; 6(14):12340-56. PubMed ID: 25895026
[TBL] [Abstract][Full Text] [Related]
44. Down-regulated FSTL5 promotes cell proliferation and survival by affecting Wnt/β-catenin signaling in hepatocellular carcinoma.
Zhang D; Ma X; Sun W; Cui P; Lu Z
Int J Clin Exp Pathol; 2015; 8(3):3386-94. PubMed ID: 26045876
[TBL] [Abstract][Full Text] [Related]
45. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
46. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.
Liu Y; Zhuang H; Cao F; Li J; Guo Y; Zhang J; Zhao Q; Liu Y
Cell Death Dis; 2021 Mar; 12(3):278. PubMed ID: 33723262
[TBL] [Abstract][Full Text] [Related]
47. Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway.
Fang D; Wang MR; Guan JL; Han YY; Sheng JQ; Tian DA; Li PY
Exp Cell Res; 2021 Sep; 406(2):112727. PubMed ID: 34370992
[TBL] [Abstract][Full Text] [Related]
48. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
49. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
[TBL] [Abstract][Full Text] [Related]
50. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
[TBL] [Abstract][Full Text] [Related]
51. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Wei W; Chua MS; Grepper S; So S
Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
[TBL] [Abstract][Full Text] [Related]
52. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
53. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells.
Wang R; Sun Q; Wang P; Liu M; Xiong S; Luo J; Huang H; Du Q; Geller DA; Cheng B
Oncotarget; 2016 Feb; 7(5):5754-68. PubMed ID: 26735577
[TBL] [Abstract][Full Text] [Related]
54. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Giovannini C; Baglioni M; Baron Toaldo M; Ventrucci C; D'Adamo S; Cipone M; Chieco P; Gramantieri L; Bolondi L
Oncotarget; 2013 Oct; 4(10):1618-31. PubMed ID: 24113128
[TBL] [Abstract][Full Text] [Related]
55. Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Nagel C; Armeanu-Ebinger S; Dewerth A; Warmann SW; Fuchs J
Exp Cell Res; 2015 Feb; 331(1):97-104. PubMed ID: 25447203
[TBL] [Abstract][Full Text] [Related]
56. Dichlorodiphenyltrichloroethane exposure induces the growth of hepatocellular carcinoma via Wnt/β-catenin pathway.
Jin XT; Song L; Zhao JY; Li ZY; Zhao MR; Liu WP
Toxicol Lett; 2014 Feb; 225(1):158-66. PubMed ID: 24355586
[TBL] [Abstract][Full Text] [Related]
57. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
Savić R; He X; Fiel I; Schuchman EH
PLoS One; 2013; 8(5):e65620. PubMed ID: 23724146
[TBL] [Abstract][Full Text] [Related]
58. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
Liu M; Bamodu OA; Kuo KT; Lee WH; Lin YK; Wu ATH; M H; Tzeng YM; Yeh CT; Tsai JT
Am J Chin Med; 2018; 46(4):891-910. PubMed ID: 29792038
[TBL] [Abstract][Full Text] [Related]
60. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]